scispace - formally typeset
K

Kelly Davies

Researcher at Clinical Trial Service Unit

Publications -  13
Citations -  3434

Kelly Davies is an academic researcher from Clinical Trial Service Unit. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 5 publications receiving 2027 citations.

Papers
More filters
Journal ArticleDOI

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials

TL;DR: Although NSAIDs increase vascular and gastrointestinal risks, the size of these risks can be predicted, which could help guide clinical decision making.
Journal ArticleDOI

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Merryn Voysey, +766 more
- 06 Mar 2021 - 
TL;DR: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.
Journal ArticleDOI

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

Jane Armitage, +98 more
- 02 Feb 2019 - 
TL;DR: A meta-analysis of data from all large statin trials to compare the effects of statin therapy at different ages observed a significant reduction in major vascular events in all age groups.
Journal ArticleDOI

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.

Xinxue Liu, +90 more
- 04 Sep 2021 - 
TL;DR: The Com-COV trial as discussed by the authors evaluated vaccine safety, reactogenicity, and immunogenicity of the BNT/ChAd schedule with a 28-day or 84-day prime-boost interval.